Exploring NUP62’s role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis

作者：Lihong Chen, Youfu He, Menghui Duan, Tianwen Yang, Yin Chen, Wei Wang, Dejun Cui, Chen Li · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1559396 · 被引用次数：20 · 研究领域：Nuclear Structure and Function、Ferroptosis and cancer prognosis、Clusterin in disease pathology

Background: NUP62, a key component of the nuclear pore complex, is closely associated with cellular functions and cancer progression. However, its expression patterns, prognostic value, and relationship with tumour immunity and drug sensitivity across multiple cancers have not been systematically studied. This study used multi-omics analyses combined with experimental validation in gastric cancer to investigate the expression, functional characteristics, and clinical relevance of NUP62 in cancer. Methods: Data from TCGA, GTEx, and CPTAC databases were used to analyse the expression, mutation characteristics, and clinical associations of NUP62. Tools such as SangerBox, TIMER 2.0, and GSEA were employed to evaluate the relationship between NUP62 and the tumour immune microenvironment, as well as its involvement in signalling pathways. Immunohistochemistry and RT-PCR were used to validate the expression of NUP62 in gastric cancer tissues. PRISM and CTRP databases were utilised to assess the correlation between NUP62 expression and drug sensitivity. Results: NUP62 was significantly upregulated in multiple cancers and was associated with poor prognosis in cancers such as clear cell renal carcinoma (KIRC), lower-grade glioma (LGG), and adrenocortical carcinoma (ACC), while playing a protective role in others, such as bladder cancer (BLCA) and stomach cancer (STAD). Functional analyses showed that NUP62 is involved in cell cycle regulation, DNA damage repair, and tumour immunity. Hi...